Abivax

ABVX

Market cap $9.53B

Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”),  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026. The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn's disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside.

These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.

• Abivax stock is taking a hit today. Why is ABVX stock falling?

Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French biotech company for months, with analysts seeing it as a prime takeover target.

Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions.

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.

Abivax remains a 'Strong Buy' due to obefazimod's positive phase 3 UC data and upcoming pivotal maintenance results in late Q2 2026. Company's differentiated mir-124 enhancer mechanism targets both inflammatory and fibrotic pathways, positioning it uniquely in the IBD therapeutic landscape. Key catalysts include 44-week phase 3 UC maintenance data and phase 2b Crohn's Disease induction results, both expected in 2026.

Biotechnology ‌company Abivax dismissed information published ​by ​French media publication "La ⁠Lettre" saying ​it had ​granted AstraZeneca exclusive access to ​confidential ​information until March 23 ‌to ⁠allow the British pharmaceutical giant ​to ​formalise ⁠a takeover ​offer.